Drug General Information (ID: DDI8DVL2Z6)
Drug Name			Ibutilide		Drug Info		Fingolimod		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiarrhythmic Agents				Selective Immunosuppressants
Structure

Mechanism of Ibutilide-Fingolimod Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Ibutilide				Fingolimod
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Ibutilide and Fingolimod

Recommended Action
Management		The use of fingolimod in patients with arrhythmias requiring treatment with class IA or class III antiarrhythmic agents has not been studied and is considered contraindicated.

References
1	Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
2	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
3	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod)."